Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22749162 | 1.00 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL243288 | 0.89 | — | — | |
| SCHEMBL22581617 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL4812594 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL23926540 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL23567016 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL20570539 | 0.89 | — | — | |
| SCHEMBL20570963 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL20570026 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 | |
| SCHEMBL17065543 | 0.89 | KDM4E (0.50) | KDM4ECYP3A4CA1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720050-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | claimed |
| CN-119822958-B | Method for preparing high-carbon ester compound by combining electrocatalytic and thermocatalytic crude acetylene and two-step cascading device | 中国科学技术大学 | 2025-06-13 | — | — | CN | claimed |
| CN-119822958-A | Method for preparing high-carbon ester compound by combining electrocatalytic and thermocatalytic crude acetylene and two-step cascading device | 中国科学技术大学 | 2025-04-15 | — | — | CN | claimed |
| WO-2024249672-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| US-12122788-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | claimed |
| US-20240327355-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-03 | — | — | US | claimed |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | claimed |
| EP-4375273-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | claimed |
| EP-4359401-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | claimed |
| EP-4313987-A2 | PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA, d.d., Novo mesto (SI) | 2024-02-07 | — | — | EP | claimed |
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | claimed |
| WO-2022271801-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | claimed |
| WO-2022207788-A2 | PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA, D.D., NOVO MESTO (SI) | 2022-10-06 | — | — | WO | claimed |
| WO-2021249877-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES | CAMBREX PROFARMACO MILANO S.R.L. (IT) | 2021-12-16 | — | — | WO | claimed |
| US-20190071789-A1 | ADDITIVE FOR SILVER-PALLADIUM ALLOY ELECTROLYTES | UMICORE GALVANOTECHNIK GMBH (DE) | 2019-03-07 | — | — | US | claimed |
| EP-3365478-A1 | ADDITIVE FOR SILVER-PALLADIUM ALLOY ELECTROLYTES | Umicore Galvanotechnik GmbH (DE) | 2018-08-29 | — | — | EP | claimed |
| EP-3159435-B1 | ADDITIVE FOR SILVER PALLADIUM ALLOY ELECTROLYTES | UMICORE GALVANOTECHNIK GMBH (DE) | 2018-05-23 | — | — | EP | claimed |
| WO-2017067985-A1 | ADDITIVE FOR SILVER-PALLADIUM ALLOY ELECTROLYTES | UMICORE GALVANOTECHNIK GMBH (DE) | 2017-04-27 | — | — | WO | claimed |
| EP-3159435-A1 | ADDITIVE FOR SILVER PALLADIUM ALLOY ELECTROLYTES | Umicore Galvanotechnik GmbH (DE) | 2017-04-26 | — | — | EP | claimed |
| US-4244739-A | ALIPHATIC SULFONIC ACID NOBLE METAL SALTS, FREE OF HYDROCHLORIC ACID METALLIZATION OF NONCONDUCTOR SUPPORTS | CAGNASSI ROBERTO | 1981-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | KDM4E 3333/4885CYP3A4 2407/4885CA1 3166/4885 |
| US-20240327355-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | BRAF, RAF1, NRAS | KDM4E 205/4885CYP3A4 1876/4885CA1 4020/4885 |
| US-12122788-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | KDM4E 3960/4885CYP3A4 726/4885CA1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.